• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP CA 19-9; IMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP CA 19-9; IMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN Back to Search Results
Model Number N/A
Device Problem No Apparent Adverse Event (3189)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 10/09/2019
Event Type  malfunction  
Manufacturer Narrative
All bio-rad controls with ca 19.9 were within the normal ranges.Siemens healthcare diagnostics is investigating the cause of the discordant ca19-9 results.The ifu states in the limitations section: "warning: do not use the advia centaur ca 19-9 assay as a screening test or for diagnosis.Do not predict disease recurrence solely on levels of advia centaur ca 19-9.Normal levels of advia centaur ca 19-9 do not always preclude the presence of disease.Note: do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals.Additionally, elevated levels of ca 19-9 can be observed in patients with nonmalignant diseases.Measurements of ca 19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.Therefore, it is important to use assayspecific values to evaluate quality control results." mdr 1219913-2019-00275 (initial result) was filed for the same event.
 
Event Description
An advia centaur xp ca 19-9 greater than 700 u/ml (positive) result was obtained for a patient sample.The patient sample was diluted and repeated.The result was positive.The positive results were reported to the physician and questioned.The patient sample was tested on an alternate method and the result was negative.A corrected report was issued.The negative result was in agreement with the clinical picture of the patient.There is no indication of a cancer diagnosis with this patient.Patient treatment was not prescribed or altered.There was no report of adverse health consequences due to the discordant ca 19-9 results.
 
Manufacturer Narrative
Siemens filed the initial mdr 1219913-2019-00276 on december 19, 2019.01/09/2020 additional information: the initial issue was reported as advia centaur xp ca19-9 patient's results were abnormally high with lot 445.Siemens cannot definitively determine the cause of this discordant result.Contributing factors such as sample integrity or preanalytical variables cannot be ruled out.Quality control was in range and no issues were noted with other patient samples indicating that the instrument and reagents were performing acceptably.There is a possibility that this represents a heterophilic (hama) interference which we know can occur in any immunoassay despite the presence of blocker substances (mouse serum and bgg in centaur ca19-9).Siemens received response from region the hbt cannot be provided in china, and no further testing can be conducted.The assay meets specification.The instrument is performing within specifications.No further evaluation of the device is required.Mdr 1219913-2019-00275 supplemental report 1 was filed for the same event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP CA 19-9
Type of Device
IMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
MDR Report Key9482610
MDR Text Key219509162
Report Number1219913-2019-00276
Device Sequence Number1
Product Code NIG
UDI-Device Identifier00630414574028
UDI-Public00630414574028
Combination Product (y/n)N
PMA/PMN Number
K031393
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 01/14/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/17/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date12/19/2019
Device Model NumberN/A
Device Catalogue Number10491244
Device Lot Number63418445
Was Device Available for Evaluation? No
Date Manufacturer Received01/09/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Age40 YR
-
-